Simeprevir Sodium is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated in chronic hepatitis c virus infection. This drug has a black box warning from the FDA. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Sovriad and Olysio. Its PubChem CID is 46866715.
Simeprevir sodium
| CAS No | 1241946-89-3 |
|---|---|
| Molecular Formula | C38H46N5NaO7S2 |
| Molecular Weight | 771.9 g/mol |
| Synonyms | sodium cyclopropylsulfonyl-[(1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]azanide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Simeprevir Sodium is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated in chronic hepatitis c virus infection.
The listed CAS number is 1241946-89-3.
The listed molecular formula is C38H46N5NaO7S2.
The listed molecular weight is 771.9 g/mol.
sodium cyclopropylsulfonyl-[(1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]azanide.
The source lists Sovriad and Olysio.